Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Vertex Pharmaceuticals: Clinical Trials & FDA Approval Profile

Vertex Pharmaceuticals (Boston, MA) sponsors 78 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 26 active protocols (11 recruiting now), 48 completed protocols, and 10 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.1%
Median Closed Enrollment vs National (145 pts)87 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Vertex Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)78
Active Pipeline (Recruiting Now)26 (11)
Completed vs Stopped Early48 / 4 (5.1%)
Median Closed Actual Enrollment87 participants
Physical Hospital Site Disclosure96.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals10 (6 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Vertex Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Boston Children's HospitalBoston, MA22
Queensland Children's HospitalSouth Brisbane, Queensland20
The Hospital for Sick ChildrenToronto, Ontario17

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Vertex Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04786262A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesPhase IIIRECRUITING
NCT06619860Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyPhase IIRECRUITING
NCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Phase II/IIIRECRUITING
NCT06628908Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPhase IIIRECRUITING
NCT05422222Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgePhase IIIACTIVE NOT RECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Vertex Pharmaceuticals Interactive Dossier, benchmark peers in Respiratory and Pulmonary, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI